Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2012 May;91(5):774-6. doi: 10.1038/clpt.2012.21.

Clopidogrel: a case for indication-specific pharmacogenetics.

Author information

1
College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, FL, USA. Johnson@cop.ufl.edu

Abstract

The CYP2C19*2 loss-of-function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta-analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications.

PMID:
22513313
PMCID:
PMC3382015
DOI:
10.1038/clpt.2012.21
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center